Items Tagged ‘velcade’

October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

By

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients with MM. The clinical trial […]

View full entry

Tags: ASCT, bortezomib, clinical trial, cyclophosphamide, dexamethasone, HOVON, Multiple Myeloma, News, Stem Cell Transplant, velcade


December 21st, 2015

Addition of Velcade® to Revlimid®/Dexamethasone Improves Survival in Newly Diagnosed Multiple Myeloma

By

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately undergo a stem cell transplant. These results were presented at the 2015 annual meeting of the American Society of Hematology in […]

View full entry

Tags: bortezomib, Multiple Myeloma, News, revlimid, velcade


April 27th, 2015

Study Demonstrates Superiority Of Kyprolis® over Velcade® in Patients With Relapsed Multiple Myeloma

By

The results from a planned interim analysis of the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis® (carfilzomib in combination with low-dose dexamethasone versus Velcade® (bortezomib) and low-dose dexamethasone have demonstrated that the Kyprolis® treated patients lived twice as long without their disease worsening. Multiple myeloma is a cancer of plasma cells, which are a […]

View full entry

Tags: bortezimib, carfilzomib, ENDEAVOR, kyprolis, Multiple Myeloma, News, velcade


February 25th, 2015

Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma

By

Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including Velcade® and an immunomodulatory (IMiD) agent. The FDA approval was partially based on the results of the […]

View full entry

Tags: bortezomib, farydak, Multiple Myeloma, News, panobinostat, Recurrent Multiple Myeloma, velcade


August 21st, 2014

Velcade Approved for Retreatment in Multiple Myeloma

By

The U.S. Food and Drug Administration (FDA) has approved Velcade® (bortezomib) for the retreatment of adult patients with multiple myeloma who had previously responded to Velcade therapy and relapsed at least six months following completion of prior Velcade treatment. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, velcade